Keros Therapeutics' Rinvatercept Shows Muscle, Bone Benefits in Phase 1 Trial

Event summary

  • Keros presented additional Phase 1 data for rinvatercept at the 2026 MDA Clinical & Scientific Conference, showing muscle mass increase, fat mass decrease, and bone mineral density improvement in healthy volunteers.
  • Proteomic analysis confirmed target engagement and anti-fibrotic, anti-inflammatory effects consistent with preclinical data.
  • Company plans to advance rinvatercept into Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
  • Preclinical data in DMD and ALS mouse models supported further development of rinvatercept.

The big picture

Keros' Phase 1 data for rinvatercept adds to the growing body of evidence targeting TGF-β signaling for neuromuscular diseases. The shift in muscle and bone composition observed supports the potential for disease-modifying effects in DMD and ALS, where current treatment options remain limited. The company's ability to advance this program will depend on maintaining this clinical momentum while navigating the competitive landscape of rare disease therapeutics.

What we're watching

Clinical Progression
Whether Phase 2 trials in DMD and ALS will confirm the muscle and bone benefits observed in healthy volunteers.
Competitive Positioning
How Keros' rinvatercept differentiates against other neuromuscular disease therapies in development.
Regulatory Pathway
The pace at which Keros can secure regulatory approvals for rinvatercept in high-unmet-need indications.